Study of BL-M08D for advanced digestive tract and other solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You have a digestive tract tumor (like stomach, bowel, or pancreas) or another solid tumor that is locally advanced or has spread.
- You have at least one tumor that can be measured on a scan.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your major organs (heart, liver, kidneys, etc.) are working well enough for the trial.
- You agree to provide a sample of your tumor tissue (from a past biopsy or a fresh one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL-M24D1, in people with advanced or metastatic digestive tract cancers or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This study tests an experimental drug called BL-M08D1 for people with head and neck cancer that has returned or spread. The drug is designed to target and destroy cancer cells, and the study will check if it is safe and how well it works.
This trial studies an experimental drug called BL-M09D1. It is given to people with certain gynecologic cancers and other solid tumors that have advanced and not responded to standard treatment. The goal is to see if the drug can help shrink or control the cancer.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.